5 news items
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
GUTS
20 May 24
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
GUTS
13 May 24
the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
GUTS
13 May 24
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
GUTS
30 Apr 24
Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
GUTS
1 Apr 24
-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation
- Prev
- 1
- Next